This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin®

Stocks in this article: RNN

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a peer reviewed study in Neuroscience Letters that validates the mechanism of action of clavulanic acid, the active compound in Serdaxin ®, the company’s lead CNS drug currently in Phase II clinical development for major depressive disorder.

The published study, “Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking,” shows that clavulanic acid enhances release of neurotransmitters such as dopamine in the brain cell by interacting with key proteins for vesicle trafficking and fusion.

“This study is significant because it confirms at the molecular and cellular levels how Serdaxin enhances the release of neurotransmitters in the brain. Previous studies demonstrated the release of serotonin and dopamine in the brain by clavulanic acid in live animals. These results strongly support that Serdaxin's CNS effects may be due to an enhanced release of the dual neurotransmitters, called as the SERDA mechanism.” said Dr. Chang Ahn, Chairman and CEO of Rexahn.

Dr. Ahn elaborated, “Because the effectiveness of currently marketed therapies that modulate serotonin reuptake is significantly limited, there exists very strong therapeutic needs for depression patients who are non-responders, are relapsed, or are non-compliant due to adverse reactions of those therapeutics. Serdaxin positions itself to address these therapeutic and safety needs as the first SERDA antidepressant with excellent safety profile.”

Dr. Michael Thase, Chairman of the Depression Scientific Advisory Board of Rexahn, said, “This study illustrates that clavulanic acid may have important effects on monoaminergic neurotransmission, that are the result of interaction with vesicle trafficking and fusion through a novel mechanism involving Munc18 and Rab proteins. Enhancing the release of both dopamine and serotonin to physiological levels in the brain may prove to have novel therapeutic implications for those who suffer from major depressive disorder and other neurological disorders.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs